We isolated four novel anaerobic species from clinical samples from men assessed for prostate cancer (as described in Hurst, Meader, Gihawi et al. 2022). Genomes of the isolates were sequenced using Illumina MiSEQ and additional MinION Nanopore sequencing where required (as described in Hurst, Meader, Gihawi et al. 2022). Whole genome sequences and genome annotated files are provided for the following novel species:
Fenollaria sporofastidiosus sp. nov. (ID: EMRHCC_24), Peptoniphilus rachelemmaiella sp. nov. (ID: EMRHCC_23), Varibaculum prostatecancerukia sp. nov. (ID: EMRHCC_39) and Porphyromonas bobii sp. nov. (ID: EMRHCC_6C).
R. Hurst, E. Meader, A. Gihawi, G. Rallapalli, J. Clark, G.L. Kay, M. Webb, K. Manley, H. Curley, H. Walker, R. Kumar, K. Schmidt, L. Crossman, R.A. Eeles, D.C. Wedge, A.G. Lynch, C.E. Massie, M. Yazbek-Hanna, M. Rochester, R.D. Mills, R.F. Mithen, M.H. Traka, R.Y. Ball, J. O’Grady, D.S. Brewer, J. Wain, C.S. Cooper, CRUK-ICGC Prostate Group. Microbiomes of Urine and the Prostate are Linked to Human Prostate Cancer Risk Groups, Eur Urol Oncol (2022), https://doi.org/10.1016/j.euo.2022.03.006
The anaerobic species are included in patent application (UK Patent Application No. 2200682.9) from the University of East Anglia/UEA Enterprises Limited regarding the application of Anaerobic Bacteria Biomarkers Set (ABBS) genera in prostate cancer.
This work was funded by Prostate Cancer UK (research grant ref RIA15-ST2-029, MA-ETNA19-003) and The Bob Champion Cancer Trust.
Submission: Norwich Medical School, University of East Anglia, UK
Less...